Preclinical News and Research

RSS
Positive results from azide drug-loaded Emulsiphan preclinical toxicity study

Positive results from azide drug-loaded Emulsiphan preclinical toxicity study

European Patent Office grants ProtAffin key patent for CellJammer discovery technology

European Patent Office grants ProtAffin key patent for CellJammer discovery technology

SOM Biotech closes first financing round and files patent application

SOM Biotech closes first financing round and files patent application

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

American Botanical Council honors excellence in herbal medicine

American Botanical Council honors excellence in herbal medicine

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

Oncothyreon 2010 net loss decreases to 15.6 million

Oncothyreon 2010 net loss decreases to 15.6 million

Idera reports $6.0 million net loss for fourth quarter 2010

Idera reports $6.0 million net loss for fourth quarter 2010

Positive results from Creabilis CT327 Phase IIa study in patients with psoriasis vulgaris

Positive results from Creabilis CT327 Phase IIa study in patients with psoriasis vulgaris

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

CTI announces final pixantrone clinical trial design for treatment of DLBCL

CTI announces final pixantrone clinical trial design for treatment of DLBCL

Experimental drug effectively shuts off MCL1 gene and induces apoptosis

Experimental drug effectively shuts off MCL1 gene and induces apoptosis

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

USPTO grants new patent to Intellect's Alzheimer's vaccine

USPTO grants new patent to Intellect's Alzheimer's vaccine

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.